Table 3

Principle outcomes of the constant effect analyses*


Comparator
Treatment
No drug treatment
Rivastigmine
Donepezil
Galantamine





1–4 mg
6–12 mg
5 mg
10 mg
16 mg

Rivastigmine






1–4 mg
3.0%** $2,880$224,222





6–12 mg
5.8% $514 $36,161
3.0% -$2,370 Dominant




Donepezil






5 mg
6.6% $1,032 $36,161
3.7% -$1,849 Dominant
0.8% $522 $158,875



10 mg
9.5% -$811 Dominant
6.7% -$3,692 Dominant
3.9% -$1,321 Dominant
3.1% -$1,843 Dominant


Galantamine






16 mg
10.2% -$1,134 Dominant
7.5% -$4,015 Dominant
4.6% -$1,644 Dominant
3.9% -$2,166 Dominant
0.8% -$323 Dominant

24 mg
10.3% -$1,366 Dominant
7.6% -$4,246 Dominant
4.7% -$1,876 Dominant
4.0% -$2,398 Dominant
0.9% -$555 Dominant
0.1% -$232 Dominant

* for each drug treatment in the rows the comparison is made relative to the approach in the column ** percent reduction in time spent requiring FTC net costs incremental cost per QALY gained

Caro et al. BMC Geriatrics 2003 3:6   doi:10.1186/1471-2318-3-6